advertisement
Abstract #119812 Published in IGR 25-1
Complement Factor B Inhibition or Deletion Is Not Sufficient to Prevent Neurodegeneration in a Murine Model of Glaucoma
Dolan K; Liao SM; Crowley M; Xiang C; Adams CM; Brown A; Vo N; Chen A; Delgado O; Buchanan N; Guo C; Prasanna GJournal of Ocular Pharmacology and Therapeutics 2024; 40: 524-535
Activation of the classical complement pathway is thought to contribute to the development and progression of glaucoma. The role of alternative complement or amplification pathways in glaucoma is not well understood. We evaluated complement factor B (FB) expression in postmortem human ocular tissues with or without glaucoma and the effect of FB inhibition and deletion in a mouse ocular hypertensive model of glaucoma induced by photopolymerized hyaluronic acid glycidyl methacrylate (HAGM). Human mRNA in human eyes was assessed by RNAscope and TaqMan. HAGM model was performed on C57BL6/J mice. The effect of FB in HAGM model was evaluated with an oral FB inhibitor and mice. Complement mRNA and proteins in mouse eyes were assessed by TaqMan and western blot, respectively. mRNA in human glaucomatous macular neural retina and optic nerve head was upregulated. mRNA is also upregulated in the HAGM model. Oral FB inhibitor, ED-79-GX17, dosed daily at 200 mg/kg for 3 days after intraocular pressure (IOP) induction in wild-type mice showed complement inhibition in ocular tissues and significantly inhibited systemic complement levels. Daily dosing of ED-79-GX17 for 30 days or deletion was also unable to prevent retinal ganglion cell or axon loss 30 days after IOP induction in mice. The alternative complement component FB may not substantially contribute to RGC loss in the HAGM mouse glaucoma model despite upregulation of expression and activation of the alternative pathway. The relevance of these findings to human glaucoma remains to be determined.
Ophthalmology, Novartis BioMedical Research (NBR), Cambridge, Massachusetts.
Full article